Literature DB >> 20224859

Prognostic value of histological and immunohistochemical characteristics for predicting the recurrence of medullary thyroid carcinoma.

A Ríos1, J M Rodríguez, J M Acosta, M D Balsalobre, N Torregrosa, J Sola, D Pérez-Flores, P Parrilla.   

Abstract

INTRODUCTION: In medullary thyroid carcinoma, there is currently no consensus about the prognostic value of histological and immunohistochemical parameters. This study was designed to analyze the value of various histological and immunohistochemical characteristics for predicting the recurrence of medullary carcinoma.
METHODS: A total of 55 cases of medullary thyroid carcinoma have been reviewed. These were operated on consecutively between 1971 and 2004 after histological confirmation. The data referring to clinical characteristics and evolution were taken from the patient's clinical history. The macroscopic, microscopic, and immunohistochemical characteristics of the tumors were taken from the pathological anatomy report.
RESULTS: In 14 (27%) cases, there was recurrence of the disease. The disease-free interval at 1 year was 88 +/- 5%; at 5 years 73 +/- 7%; at 10 years 73 +/- 7%; at 15 years 61 +/- 10%; and at 20 years or more 61 +/- 10%. Of the histological parameters, only vascular invasion (0.0098) was related to a higher relapse rate. No epidemiological variable or immunohistochemical marker was associated with relapse. However, it was found that staging (P = 0.0102), as well as tumor size (P = 0.0211) and lymph node affectation (P = 0.0012), are factors significantly related to relapse of the disease. According to Cox's regression model, the only variable with a statistically significant effect was vascular invasion (P = 0.0056; odds ratio = 5.2308).
CONCLUSIONS: The overall recurrence rate was 27%, and the main independent prognostic factor of recurrence was tumoral vascular invasion at diagnosis. Staging, tumor size, and lymph node metastasis are prognostic factors of recurrence, although they are not significant in the multivariate analysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20224859     DOI: 10.1245/s10434-010-1021-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.

Authors:  P Lennon; S Deady; N White; D Lambert; M L Healy; A Green; J Kinsella; C Timon; J P O' Neill
Journal:  Ir J Med Sci       Date:  2016-04-15       Impact factor: 1.568

2.  External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort.

Authors:  Elena Vissio; Francesca Maletta; Jessica Fissore; Simona Osella Abate; Francesca Retta; Maria Pia Brizzi; Alessandro Piovesan; Ruth Rossetto Giaccherino; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2022-05-18       Impact factor: 4.056

3.  Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Authors:  Max Czajkowski; Daniel Kaemmerer; Jörg Sänger; Guido Sauter; Ralph M Wirtz; Stefan Schulz; Amelie Lupp
Journal:  BMC Cancer       Date:  2022-07-07       Impact factor: 4.638

4.  Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome.

Authors:  Bayan Alzumaili; Bin Xu; Philip M Spanheimer; R Michael Tuttle; Eric Sherman; Nora Katabi; Snjezana Dogan; Ian Ganly; Brian R Untch; Ronald A Ghossein
Journal:  Mod Pathol       Date:  2020-04-20       Impact factor: 7.842

5.  A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis.

Authors:  Talia L Fuchs; Anthony J Nassour; Anthony Glover; Mark S Sywak; Stan B Sidhu; Leigh W Delbridge; Roderick J Clifton-Bligh; Matti L Gild; Venessa Tsang; Bruce G Robinson; Adele Clarkson; Amy Sheen; Loretta Sioson; Angela Chou; Anthony J Gill
Journal:  Am J Surg Pathol       Date:  2020-10       Impact factor: 6.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.